Frédéric Bost

12.9k total citations · 2 hit papers
95 papers, 6.7k citations indexed

About

Frédéric Bost is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Frédéric Bost has authored 95 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Molecular Biology, 24 papers in Cancer Research and 18 papers in Oncology. Recurrent topics in Frédéric Bost's work include Metabolism, Diabetes, and Cancer (23 papers), Cancer, Hypoxia, and Metabolism (17 papers) and Cancer-related Molecular Pathways (12 papers). Frédéric Bost is often cited by papers focused on Metabolism, Diabetes, and Cancer (23 papers), Cancer, Hypoxia, and Metabolism (17 papers) and Cancer-related Molecular Pathways (12 papers). Frédéric Bost collaborates with scholars based in France, United States and Monaco. Frédéric Bost's co-authors include Y. Le Marchand‐Brustel, Jean‐François Tanti, Bernard Binétruy, Issam Ben Sahra, Kathiane Laurent, Leslie Caron, Myriam Aouadi, Sophie Giorgetti‐Peraldi, Patrick Auberger and Dan Mercola and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Frédéric Bost

88 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level

2008 732 citations Issam Ben Sahra, Kathiane Laurent et al. Oncogene profile →
Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1

2011 526 citations Claire Regazzetti, Guillaume Robert et al. Cancer Research profile →

Peers

Countries citing papers authored by Frédéric Bost

Since Specialization

Citations

This map shows the geographic impact of Frédéric Bost's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Bost with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Bost more than expected).

Fields of papers citing papers by Frédéric Bost

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Bost. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Bost. The network helps show where Frédéric Bost may publish in the future.

Co-authorship network of co-authors of Frédéric Bost

This figure shows the co-authorship network connecting the top 25 collaborators of Frédéric Bost. A scholar is included among the top collaborators of Frédéric Bost based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédéric Bost. Frédéric Bost is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prostate cancer and pollution: Dangerous connections 2025 ·Annales d Endocrinologie ·(unknown), (unknown), Frédéric Bost, Nicolas Chevalier	0
2	YAP1 modulation of primary cilia‐mediated ciliogenesis in 2D and 3D prostate cancer models 2024 ·FEBS Letters ·Yingbo Guo, (unknown), Marie Irondelle, Pascal Peraldi, Frédéric Bost, Nathalie M. Mazure	0
3	HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma 2024 ·Cell Death Discovery ·Julie Contenti, Yongjian Guo, Magalie Larcher, (unknown), Matthieu Rouleau, Marie Irondelle, (unknown), (unknown), (unknown), Florence Pédeutour, Issam Ben‐Sahra, (unknown), (unknown), Luca Tiberi, Guillaume Robert, Célio Pouponnot, Frédéric Bost, Nathalie M. Mazure	2
4	Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS‐010759 2024 ·Molecular Oncology ·(unknown), Amine Belaïd, (unknown), (unknown), Pascal Peraldi, Matthieu Rouleau, Nathalie M. Mazure, Frédéric Bost	23
5	The troglitazone derivative EP13 disrupts energy metabolism through respiratory chain complex I inhibition in breast cancer cells and potentiates the antiproliferative effect of glycolysis inhibitors 2024 ·Cancer Cell International ·Claire Muller, (unknown), Jérôme Kluza, William Laine, (unknown), Frédéric Bost, Michel Boisbrun, Sabine Mazerbourg, Stéphane Flament	2
6	Cell Plasticity in a Mouse Model of Benign Prostate Hyperplasia Drives Amplification of Androgen-Independent Epithelial Cell Populations Sensitive to Antioxidant Therapy 2023 ·American Journal Of Pathology ·(unknown), (unknown), (unknown), (unknown), Marine Luka, Natascha Pigat, (unknown), E. Navarro, J. Anract, Nicolas Barry Delongchamps, Nicolas Cagnard, Frédéric Bost, Ivan Nemazanyy, Olivier Petitjean, Ahmed Hamaï, Mickaël Ménager, Stéfano Palea, Jacques‐Emmanuel Guidotti, Vincent Goffin	3
7	The mitochondrial NADH shuttle system is a targetable vulnerability for Group 3 medulloblastoma in a hypoxic microenvironment 2023 ·Cell Death and Disease ·Julie Contenti, Yongjian Guo, (unknown), Marie Irondelle, Matthieu Rouleau, (unknown), (unknown), Luca Tiberi, Issam Ben‐Sahra, Frédéric Bost, Nathalie M. Mazure	6
8	Discovery of a new molecule inducing melanoma cell death: dual AMPK/MELK targeting for novel melanoma therapies 2021 ·Cell Death and Disease ·Emilie Jaune, (unknown), Cyril Ronco, (unknown), Patricia Abbe, (unknown), (unknown), Guillaume E. Béranger, (unknown), Frédéric Bost, Maéva Gesson, Meri K. Tulić, Paul Hofman, Robert Ballotti, Thierry Passeron, Thomas Botton, Rachid Benhida, Stéphane Rocchi	19
9	TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer 2021 ·Clinical Genitourinary Cancer ·(unknown), Delphine Borchiellini, (unknown), Aline Guillot, Jean-Baptiste Paoli, Dominique Besson, Werner Hilgers, Frank Priou, Claude El Kouri, Benjamin Hoch, Jean‐Laurent Deville, Renaud Schiappa, Sandrine Pacquelet, G. Milano, Jean‐François Tanti, Frédéric Bost, (unknown)	34
10	Co‐culture of human fibroblasts, smooth muscle and endothelial cells promotes osteopontin induction in hypoxia 2020 ·Journal of Cellular and Molecular Medicine ·(unknown), Julie Contenti, Maeva Dufies, Julien Parola, Matthieu Rouleau, (unknown), Jean‐François Peyron, Lucilla Fabbri, Réda Hassen‐Khodja, Jacques Pouysségur, Frédéric Bost, Elixène Jean‐Baptiste, Alan Dardik, Nathalie M. Mazure	7
11	PGC1α Inhibits Polyamine Synthesis to Suppress Prostate Cancer Aggressiveness 2019 ·Cancer Research ·(unknown), Stéphanie Torrino, Maeva Dufies, Zied Djabari, (unknown), (unknown), Emilie Jaune, Kathiane Laurent, Nicolas Nottet, Jean‐François Michiels, Maéva Gesson, Stéphane Rocchi, Nathalie M. Mazure, M. Durand, Jean‐François Tanti, Damien Ambrosetti, Stéphan Clavel, Issam Ben‐Sahra, Frédéric Bost	29
12	Energy disruptors: rising stars in anticancer therapy? 2016 ·Oncogenesis ·Frédéric Bost, (unknown), Jean‐François Tanti, Stéphan Clavel	88
13	Inhibition of the GTPase Rac1 Mediates the Antimigratory Effects of Metformin in Prostate Cancer Cells 2014 ·Molecular Cancer Therapeutics ·Béatrice Dirat, Isabelle Ader, Muriel Golzio, (unknown), Amel Mettouchi, Kathiane Laurent, Frédéric Larbret, Bernard Malavaud, Mireille Cormont, Emmanuel Lemichez, Olivier Cuvillier, Jean‐François Tanti, Frédéric Bost	34
14	Metformin: A metabolic disruptor and anti-diabetic drug to target human leukemia 2014 ·Cancer Letters ·(unknown), Issam Ben‐Sahra, Frédéric Bost, Jean‐François Peyron	53
15	Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death 2012 ·Cell Death and Differentiation ·Issam Ben‐Sahra, Béatrice Dirat, Kathiane Laurent, Alexandre Puissant, Patrick Auberger, Andrei V. Budanov, Jean‐François Tanti, Frédéric Bost	127
16	Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1 breakdown → 2011 ·Cancer Research ·(unknown), Claire Regazzetti, Guillaume Robert, Kathiane Laurent, Y. Le Marchand‐Brustel, Patrick Auberger, Jean‐François Tanti, Sophie Giorgetti‐Peraldi, Frédéric Bost	526
17	Targeting Cancer Cell Metabolism: The Combination of Metformin and 2-Deoxyglucose Induces p53-Dependent Apoptosis in Prostate Cancer Cells 2010 ·Cancer Research ·Issam Ben Sahra, Kathiane Laurent, Sandy Giuliano, Frédéric Larbret, Gilles Ponzio, Pierre Gounon, Y. Le Marchand‐Brustel, Sophie Giorgetti‐Peraldi, Mireille Cormont, Corine Bertolotto, Marcel Deckert, Patrick Auberger, Jean‐François Tanti, Frédéric Bost	434
18	The defective transforming phenotype of c-Jun Ala63/73 is rescued by mutation of the C-terminal phosphorylation site 2001 ·Oncogene ·Frédéric Bost, Leslie Caron, Emmanuel Vial, Nicole Montreau, (unknown), (unknown), Libert H.K. Defize, Marc Castellazzi, Bernard Binétruy	5
19	[24] Antisense methods for discrimination of phenotypic properties of closely related gene products: Jun kinase family 2000 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Frédéric Bost, Robert A. McKay, Nicholas M. Dean, Olga Potapova, Dan Mercola	10
20	Isolation and characterization of the human inter‐α‐trypsin inhibitor heavy‐chain H1 gene 1993 ·European Journal of Biochemistry ·Frédéric Bost, Jeannette Bourguignon, Jean‐Pierre Martin, Richard Sesboüé, Luc Thiberville, Maryam Mehrpour	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact